Eletriptan review.
Eletriptan is a selective, high affinity serotonin 5-HT(1B/1D)-receptor agonist which is rapidly absorbed and has a long half-life in plasma. Eletriptan has been shown to be effective and well tolerated in randomised, double-blind, placebo-controlled acute migraine trials and long-term open-label trials. Eletriptan maintains a consistency of response across three attacks and patients continue to respond to eletriptan for at least up to 1 year. Eletriptan has been compared with sumatriptan, zolmitriptan, naratriptan and ergotamine/caffeine in placebo-controlled, randomised, head-to-head trials, and has shown better efficacy with similar adverse events. In a large triptan meta-analysis, including 53 trials and > 24,000 patients, eletriptan 80 mg showed better efficacy, similar consistency but lower tolerability compared with sumatriptan 100 mg. Eletriptan has also shown efficacy in difficult-to-treat patients who were dissatisfied with their previous treatment with sumatriptan, rizatriptan, nonsteroidal anti-inflammatory drugs or Excedrin.
Färkkilä
Markus
M
Department of Neurology, University Hospital Haartmaninkatu 4, 00290 Helsinki, Finland. markus.farkkila@hus.fi
Kallela
Mikko
M
D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000378:metabolism; D011759:Pyrrolidines / Q000378:metabolism / Q000627:therapeutic use*; D017366:Serotonin Receptor Agonists / Q000378:metabolism / Q000627:therapeutic use*; D014363:Tryptamines / Q000378:metabolism / Q000627:therapeutic use*
D011759:Pyrrolidines; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C115647:eletriptan